Q-omics provides the consensus-scored SRIP1 profile across patient tissues and cancer cell-line models. SRIP1 expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, SRIP1 is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, SRIP1 RNA expression shows 4,114 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, KIRC, and STAD as cancer lineages where SRIP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SRIP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SRIP1 survival associations across molecular data types. SRIP1 RNA expression shows survival associations in the most cancer types (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SRIP1 RNA expression–survival associations across cancer types. High SRIP1 expression shows unfavorable associations in UCEC, THYM, HNSC, ACC and READ, but favorable associations in LUSC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for SRIP1 RNA expression.
This table summarizes SRIP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SRIP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SRIP1 shows higher tumor expression in KIRC. The KIRC box plot shows higher SRIP1 RNA expression in tumor versus normal tissue (log2 FC = +0.028, t-test p = .029).
This table shows molecular features associated with SRIP1 in patient tissues and cancer cell lines. In patient samples, SRIP1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
